Paxillin is overexpressed in many carcinomas, including bladder cancer [33], ESCC [34], [35], hepatocellular carcinoma (HCC) [36], NSCLC [37], salivary adenoid cystic carcinoma [38], and floor of mouth carcinoma [39]. This evidence concerns the gene PXN and esophageal squamous cell carcinoma.